Medconn Diagnostics Demonstrates Innovative Hematology and HbA1c Solutions at World Health Expo Labs Kuala Lumpur 2025

Kuala Lumpur, Malaysia – Medconn Diagnostics proudly exhibited at World Health Expo Labs Kuala Lumpur 2025 （Formaly Medlab Assia）, one of the region's most prominent healthcare exhibitions. The event drew substantial interest from industry professionals, with many visitors exploring Medconn's latest diagnostic innovations at our exhibition booth.

The highlight of our presentation was Medconn's premium HPLC HbA1c analyzer, engineered for precise diabetes management and hemoglobinopathy testing. The MQ-8000 model garnered particular attention as part of an integrated Hematology-HbA1c automated line, exemplifying our dedication to comprehensive laboratory solutions. This advanced HbA1c system offers multi-parameter detection, including accurate measurement of HbA1c, common variants, HbA2, and HbF, making it an invaluable tool for both diabetes care and thalassemia screening.

Hematology-HbA1c automated line

Our hematology display featured MH-120, a high-performance five-part differential analyzer, which provides enhanced diagnostic capabilities through parameters such as reticulocytes (RET), immature granulocytes (IG), pRBC for malaria detection, and atypical lymphocytes, offering clinicians more comprehensive data for diagnostic decisions.

From left to right:MH-120, MQ-8000*2

Visitors also showed keen interest in Medconn's point-of-care testing portfolio, especially our cardiovascular testing system designed for rapid emergency diagnostics. Additionally, our AI-enhanced diagnostic system and Q-lab （third party quality control syetem）attracted attention for its ability to optimize laboratory workflows and improve diagnostic accuracy through intelligent data analysis.

With expanding global operations, continuous research and development investments, Medconn Diagnostics reinforces its position as a reliable clinical laboratory partner throughout Asia and beyond.